MDM2 and neoplasm: In a separate in vitro analysis, it was shown that combination MDM2 inhibition plus doxorubicin was associated with significantly reduced tumor growth compared with doxorubicin monotherapy, suggesting that the addition of MDM2 inhibition to conventional cytotoxic therapy might also be beneficial (120).